Hearing loss

Signia AX and Signia Insio Charge&Go AX named CES 2022 Innovation Awards Honorees

Thursday, October 14, 2021 - 10:39pm

The CES Innovation Awards program is an annual competition honoring outstanding design and engineering in 27 consumer technology product categories.

Key Points: 
  • The CES Innovation Awards program is an annual competition honoring outstanding design and engineering in 27 consumer technology product categories.
  • The Signia Insio Charge&Go AX, which was named Honoree in the Wearables category, is a Bluetooth-capable, rechargeable, custom in-the-ear hearing aid based on the unique Signia AX platform.
  • The Insio Charge&Go AX is the second family of Signia hearing aids built upon the AX platform, following the successful Spring 2021 launch of the Pure Charge&Go T AX receiver-in-canal (RIC) hearing aids.
  • 1The CES Innovation Awards are based upon descriptive materials submitted to the judges.

Oticon More™ hearing aids now offer more sound, more music, more choice and freedom

Thursday, October 14, 2021 - 3:19pm

TORONTO, Oct. 14, 2021 (GLOBE NEWSWIRE) -- With the launch of Oticon More™, Oticon delivered the world’s first hearing aid to give the brain the full perspective, providing clients with outstanding sound quality that outperformed top competitors in both objectivei and subjectiveii testing. Now, Oticon is pleased to announce that they are extending the line of Oticon More™ hearing aids to enable hearing care professionals to offer this superior hearing experience to even more clients.

Key Points: 
  • Now, Oticon is pleased to announce that they are extending the line of Oticon More hearing aids to enable hearing care professionals to offer this superior hearing experience to even more clients.
  • A protective lid, designed for travel, keeps hearing aids safe, and the SmartCharger automatically removes moisture from users hearing aids.
  • This new charging solution joins the desk charger, so that hearing care professionals can offer clients a choice of power sources alongside rechargeable Oticon More hearing aids to suit individual preference.
  • Utilizing users hearing aids, hearing care professionals can now offer even more flexible remote hearing care to clients via RemoteCare.

DGAP-News: Precisis concludes funding round of €20 million for its bioelectric brain stimulation system

Thursday, October 14, 2021 - 12:08pm

Heidelberg, Germany, [14 October 2021] - Precisis AG, based in Heidelberg, announced that it has successfully concluded a funding round of 20 million with Cochlear Limited.

Key Points: 
  • Heidelberg, Germany, [14 October 2021] - Precisis AG, based in Heidelberg, announced that it has successfully concluded a funding round of 20 million with Cochlear Limited.
  • Precisis is a medical technology company that develops minimally invasive brain stimulation methods to relieve epilepsy patients from their symptoms.
  • The additional funding will be used to support ongoing clinical studies and to further advance EASEE(R), an implantable bioelectric brain stimulation system that explores novel approaches to treating epilepsy.
  • Angela Liedler, MD, CEO of Precisis AG, is thrilled: "This funding round is an important step in the advancement of bioelectric brain stimulation.

Americans Want Professionals' Guidance on Hearing Care, Know Little About Coming Over-the-Counter Hearing Aids (OTCs)

Wednesday, October 13, 2021 - 1:05pm

Bishop continued: "With the impending availability of these products, the public should know that audiologists will be a key resource for them.

Key Points: 
  • Bishop continued: "With the impending availability of these products, the public should know that audiologists will be a key resource for them.
  • We'd recommend anyone with concern about their hearing get a hearing evaluation as a first step, even if they intend to purchase an OTC hearing aid.
  • The polling results also show that most Americans have little awareness of the coming OTC hearing aids, and many are wary of this new category of medical devices.
  • The path to market for OTC hearing aids began in 2017 following passage of the Over-the-Counter Hearing Aid Act.

Otonomy Announces Publication of Phase 1/2 Trial Results Showing Tinnitus Improvement in Patients Receiving OTO-313

Tuesday, October 12, 2021 - 12:30pm

This is also an encouraging moment for clinicians who currently lack any drug therapy to reduce the severity of tinnitus that patients experience.

Key Points: 
  • This is also an encouraging moment for clinicians who currently lack any drug therapy to reduce the severity of tinnitus that patients experience.
  • "Availability of the Phase 1/2 trial results is constructive for our efforts to maintain the favorable pace of patient enrollment in the ongoing Phase 2 trial that is on-track with our anticipated timing for results in mid-2022, said David A. Weber, Ph.D., president and CEO of Otonomy.
  • The exploratory efficacy cohort of the Phase 1/2 trial included 31 evaluable patients with persistent unilateral tinnitus of at least moderate severity based on the TFI.
  • In 2020, we reported positive results from a Phase 1/2 trial of OTO-313 in patients with unilateral tinnitus of at least moderate severity.

Cochlear announces FDA approval and FDA clearance of first-of-its-kind Remote Care capabilities for Nucleus and Baha Systems

Tuesday, October 12, 2021 - 2:06pm

The FDA approval for the cochlear implant solution and FDA clearance for the Baha solution are the first step in commercializing the product offering, anticipated spring 2022, and complement Cochlear's existing Remote Care offerings.

Key Points: 
  • The FDA approval for the cochlear implant solution and FDA clearance for the Baha solution are the first step in commercializing the product offering, anticipated spring 2022, and complement Cochlear's existing Remote Care offerings.
  • Cochlear's Remote Care solutions offer hearing implant patients the convenience of quality hearing care without the need to visit a clinic.
  • Connected Care offers new tools that give hearing care professionals the flexibility to customize patient care, increase clinic efficiency and maximize their time delivering quality patient care.
  • Cochlear anticipates Remote Assist approval in Canada to be obtained in late 2021 for the Nucleus System and early 2022 for the Baha System.

Audiology Profession Publishes Standard Practices in Hearing Aid Fitting

Monday, October 11, 2021 - 3:21pm

Because it can be easily treated with hearing aids, hearing loss is also one of the most manageable conditions associated with cognitive decline.

Key Points: 
  • Because it can be easily treated with hearing aids, hearing loss is also one of the most manageable conditions associated with cognitive decline.
  • Audiology Practice Standards Organization (APSO) has published a formal standard of practice for fitting hearing aids to adult patients.
  • The standard is based on common clinical practices of audiologists across the U.S., as well as research into the practices that achieve expected outcomes with hearing aids.
  • Audiologists counsel patients, select the most appropriate hearing aids, fit the hearing aids, and verify that the hearing aids are performing to meet each individual's hearing loss prescription.

Twersky Law Group Announces a Class Action Against Eargo, Inc. ("Eargo") and Presents Investors with an Opportunity to Recover Losses, File Claims and Preserve Their Rights! If You Lost Money in Eargo Stock, Contact Us by 12/6/2021

Monday, October 11, 2021 - 2:45pm

Eargo is a medical device company that focuses on manufacturing hearing aids and other devices for hearing loss.

Key Points: 
  • Eargo is a medical device company that focuses on manufacturing hearing aids and other devices for hearing loss.
  • This plaintiff must also be an adequate representative that will act on behalf of all other class members in the lawsuit.
  • ABOUT TWERSKY LAW GROUP: Atara Twersky, Esq., Principal at Twersky Law Group has been successfully and thoughtfully representing clients across the globe in securities, antitrust and shareholder litigation.
  • For more information concerning this case or the Twersky Law Group, visit our website or contact Atara Twersky's by phone at (212) 365-0588.

Audibel Launches "Arc AI" Hearing Aid Line

Thursday, October 7, 2021 - 1:47pm

"The smartest hearing aid just got smarter," said Achin Bhowmik, Ph.D., Chief Technology Officer for Audibel.

Key Points: 
  • "The smartest hearing aid just got smarter," said Achin Bhowmik, Ph.D., Chief Technology Officer for Audibel.
  • "The Arc AI will redefine how hearing loss is addressed for the next decade, and we at Audibel are proud to lead the way."
  • According to Keri L. Ruf, MA, Regional Managing Director at Audibel, exceptional sound quality is at the heart of the Arc AI product line.
  • "Your hearing aid should adjust to you, not the other way around," said Ruf.

Sensorion Hosting Key Opinion Leader Webinar with Dr Nicole C. Schmitt on Cisplatin-Induced Ototoxicity on October 28, 2021

Thursday, October 7, 2021 - 6:30am

The webinar will feature a presentation by Key Opinion Leader Nicole C. Schmitt, MD, FACS (Emory University) who will provide an overview on hearing loss caused by cisplatin-induced ototoxicity, its epidemiology, the current treatment landscape, and the unmet medical need in adults.

Key Points: 
  • The webinar will feature a presentation by Key Opinion Leader Nicole C. Schmitt, MD, FACS (Emory University) who will provide an overview on hearing loss caused by cisplatin-induced ototoxicity, its epidemiology, the current treatment landscape, and the unmet medical need in adults.
  • Nicole C. Schmitt, MD, FACS, obtained her Medical Degree from Washington University School of Medicine in St. Louis, Missouri.
  • Dr. Schmitt is a head and neck surgical oncologist and scientist at Emory University in Atlanta, Georgia, USA.
  • Dr. Schmitt has been studying molecular mechanisms, incidence, and prevention strategies for cisplatin-induced ototoxicity since 2007.